These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, ...

Transient paralysis indicates hyperkalemic periodic paralysis, and fluctuating myotonia indicates potassium-aggravating myotonia. 10,11 Electrophysiological studies can also provide information ...

Dr. Anh Nguyen brings significant experience to his role as CMO, having led the development of first-in-class therapies ...

Medically reviewed by Daniel Combs, MD More than 50 million Americans have a sleep disorder. Regularly having trouble ...

Good data not only helps formulate strategy, but also reduces the risk of policy paralysis. Over the last 75 years, data ...

Justice Lalit warns of constitutional challenges to synchronising Lok Sabha and state elections and advocates a phased implementation of ‘one nation, one poll’ ...

The Ethiopian government launched a nationwide polio vaccination campaign on Wednesday, targeting more than 13.8 million ...